These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 24429479)

  • 41. A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma.
    Beauchesne P; Quillien V; Faure G; Bernier V; Noel G; Quetin P; Gorlia T; Carnin C; Pedeux R
    Int J Cancer; 2016 Mar; 138(6):1538-44. PubMed ID: 26501997
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study.
    Liu YE; Lin Q; Meng FJ; Chen XJ; Ren XC; Cao B; Wang N; Zong J; Peng Y; Ku YJ; Chen Y
    Radiat Oncol; 2013 Aug; 8(1):198. PubMed ID: 23937855
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.
    Scoccianti S; Detti B; Sardaro A; Iannalfi A; Meattini I; Leonulli BG; Borghesi S; Martinelli F; Bordi L; Ammannati F; Biti G
    Anticancer Drugs; 2008 Jul; 19(6):613-20. PubMed ID: 18525321
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
    Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
    Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme.
    Floyd NS; Woo SY; Teh BS; Prado C; Mai WY; Trask T; Gildenberg PL; Holoye P; Augspurger ME; Carpenter LS; Lu HH; Chiu JK; Grant WH; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):721-6. PubMed ID: 14967426
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme.
    Seidlitz A; Siepmann T; Löck S; Juratli T; Baumann M; Krause M
    Radiat Oncol; 2015 Aug; 10():172. PubMed ID: 26276734
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
    Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
    Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.
    Ney DE; Carlson JA; Damek DM; Gaspar LE; Kavanagh BD; Kleinschmidt-DeMasters BK; Waziri AE; Lillehei KO; Reddy K; Chen C
    J Neurooncol; 2015 Mar; 122(1):135-43. PubMed ID: 25524817
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
    Lewitzki V; Klement RJ; Kosmala R; Lisowski D; Flentje M; Polat B
    Radiat Oncol; 2019 Dec; 14(1):227. PubMed ID: 31831026
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
    Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
    J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
    Stupp R; Dietrich PY; Ostermann Kraljevic S; Pica A; Maillard I; Maeder P; Meuli R; Janzer R; Pizzolato G; Miralbell R; Porchet F; Regli L; de Tribolet N; Mirimanoff RO; Leyvraz S
    J Clin Oncol; 2002 Mar; 20(5):1375-82. PubMed ID: 11870182
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.
    Silvani A; Lamperti E; Gaviani P; Eoli M; Fiumani A; Salmaggi A; Falcone C; Filippini G; Botturi A; Boiardi A
    J Neurooncol; 2008 Apr; 87(2):143-51. PubMed ID: 17576523
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Regorafenib in glioblastoma recurrence: A case report.
    Detti B; Scoccianti S; Lucidi S; Maragna V; Teriaca MA; Ganovelli M; Desideri I; Lorenzetti V; Scoccimarro E; Greto D; Livi L
    Cancer Treat Res Commun; 2021; 26():100263. PubMed ID: 33338858
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.
    Addeo R; Caraglia M; De Santi MS; Montella L; Abbruzzese A; Parlato C; Vincenzi B; Carraturo M; Faiola V; Genovese M; Cennamo G; Del Prete S
    J Neurooncol; 2011 May; 102(3):417-24. PubMed ID: 20694830
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution.
    Joo JD; Kim H; Kim YH; Han JH; Kim CY
    J Korean Med Sci; 2015 Nov; 30(11):1597-603. PubMed ID: 26539003
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
    Song A; Bar-Ad V; Martinez N; Glass J; Andrews DW; Judy K; Evans JJ; Farrell CJ; Werner-Wasik M; Chervoneva I; Ly M; Palmer JD; Liu H; Shi W
    J Neurooncol; 2020 May; 147(3):653-661. PubMed ID: 32206976
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment outcomes of hypofractionated radiotherapy combined with temozolomide followed by bevacizumab salvage therapy in glioblastoma patients aged > 75 years.
    Matsuda KI; Sakurada K; Nemoto K; Kayama T; Sonoda Y
    Int J Clin Oncol; 2018 Oct; 23(5):820-825. PubMed ID: 29796740
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial.
    Mao Y; Yao Y; Zhang LW; Lu YC; Chen ZP; Zhang JM; Qi ST; You C; Wang RZ; Yang SY; Zhang X; Wang JS; Chen JX; Yang QY; Shen H; Li ZY; Wang X; Ma WB; Yang XJ; Zhen HN; Zhou LF
    Chin Med J (Engl); 2015 Oct; 128(20):2751-8. PubMed ID: 26481741
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The outcomes of concomitant radiation plus temozolomide followed by adjuvant temozolomide for newly diagnosed high grade gliomas: the preliminary results of single center prospective study.
    Shawky H; Abo Hamar AH; Galal S; Zakaria F; El-Shorbagy D
    J Egypt Natl Canc Inst; 2009 Jun; 21(2):107-19. PubMed ID: 21057562
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic factors in glioblastoma patients managed with radiotherapy combined with temozolomide.
    Peponi E; Tourkantonis I; Tasiou I; Pavlidis N; Pentheroudakis G; Tsekeris P
    J BUON; 2014; 19(3):718-23. PubMed ID: 25261658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.